

IN THE CLAIMS

Please amend the claims as follows:

1-17. (Cancelled)

18. (Previously Presented) The medical device of claim 80, wherein the medical device is a stent.

19. (Currently Amended) The medical device of claim 80, wherein the ~~first~~ polymer covers all or a portion of the surface in a thickness of about 100 nm to 1 cm.

20. (Currently Amended) The medical device of claim 80, wherein the ~~first~~ polymer covers all or a portion of the surface in a thickness of about 0.5 μ m to about 2.0 mm.

21. (Currently Amended) The medical device of claim 80, wherein the salicylic acid is disassociated from the ~~first~~ polymer over a period of about 2 days to about 2 years.

22-29. (Cancelled)

30. (Currently Amended) A medical device of claim 80, wherein a third active agent is dispersed within the polymer matrix of the ~~first~~ polymer such that the third active agent is released upon degradation of the ~~first~~ polymer.

31. (Cancelled)

32. (Currently Amended) A medical device of claim 80, wherein a third active agent is appended to the ~~first~~ polymer such that the third active agent is released under physiological conditions.

33-39. (Cancelled)

40. (Previously Presented) A stent of claim 18, comprising at least two or more surfaces.

41. (Currently Amended) A stent of claim 40, wherein all or a portion of the two or more surfaces are covered with the ~~first~~ polymer.

42-55. (Cancelled)

56. (Currently Amended) A stent of claim 41, wherein the ~~first~~ polymer covers all or a portion of the surface in a thickness of about 100 nm to 1 cm.

57. (Currently Amended) A stent of claim 41, wherein the ~~first~~ polymer covers all or a portion of the surface in a thickness of about 0.5 μ m to about 2.0 mm.

58. (Currently Amended) A stent of claim 41, wherein the active agent is disassociated from the ~~first~~ polymer over a period of about 2 days to about 2 years.

59-79. (Canceled)

80. (Currently Amended) A medical device having at least one surface, comprising: 1) a ~~first~~ polymer comprising salicylic acid incorporated into the polymer backbone on all or a portion of the surface, wherein the salicylic acid is disassociated from the polymer upon hydrolysis; and 2) a second active agent selected from paclitaxel and rapamycin that is dispersed within the polymer matrix of the ~~first~~ polymer such that the second active agent is released upon degradation of the ~~first~~ polymer.

81. (Previously Presented) The device of claim 80 wherein the second agent is paclitaxel.

82. (Previously Presented) The device of claim 80 wherein the second agent is rapamycin.